PRIMOCABG II Investigators. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials - Smith, PK; Shernan, SK; Chen, JC (J Thorac Cardiovasc Surg, 2011)
et al.